Cardiff Oncology, Inc. (CRDF)

Market Cap	174.96M
Revenue (ttm)	683,000
Net Income (ttm)	-45.46M
Shares Out	66.52M
EPS (ttm)	-0.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	835,406
Open	2.510
Previous Close	2.490
Day's Range	2.500 - 2.710
52-Week Range	2.010 - 5.640
Beta	1.80
Analysts	Strong Buy
Price Target	12.00 (+356.27%)
Earnings Date	May 8, 2025

About CRDF

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: CRDF
• Website: https://www.cardiffoncology.com

Financial Performance

In 2024, Cardiff Oncology's revenue was $683,000, an increase of 39.96% compared to the previous year's $488,000. Losses were -$45.46 million, 9.62% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for CRDF stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 356.27% from the latest price.

Price Target

$12.0

(356.27% upside)

Analyst Consensus: Strong Buy